Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “10 mg tablets; administered at a loading dose of 20 mg twice daily for 4 days, followed by a maintenance dose of 10 mg once daily for up to 24 weeks”In the company’s words, NCT07282210 on ClinicalTrials.gov
- Tested for
- Sickle Cell Disease, Sickle Cell Anaemia, Sickle Cell Anemia
- Main trialPhase 2
- “SIL-8301 (senicapoc) is being developed for the chronic treatment of patients with sickle cell disease in both adults and children. The purpose of this study is to compare the effects of senicapoc to placebo in patients with sickle cell disease that have had fewer than 2 acute sickle-related painful crises per year over the preceding 2 years, and have a predominantly hemolytic phenotype, defined as evidence of ongoing hemolysis and a baseline Hb of 9.5 g/dL or less, despite receiving hydroxyurea (an oral drug used for treatment of sickle cell disease) as standard of care. Participants will…”In the company’s words, NCT07282210 on ClinicalTrials.gov
- Other names
- SIL-8301
Other drugs for Sickle Cell Disease
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- CTX001Vertex Pharmaceuticals · Phase 3
- L-citrullineAsklepion Pharmaceuticals, LLC · Phase 3
- RilzabrutinibSanofi · Phase 3
- EtavopivatNovo Nordisk · Phase 3
Coming up1
- Oct 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2029 | Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype | |
| Phase 2Authorised | not given | Senicapoc in patients with Progressive Fibrotic ILD (Interstitial Lung Disease) or IPF (Idiopathic Pulmonary Fibrosis) to prevent progression. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026